Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3876-3888

  Goyama, Susumu ^a   Schibler, Janet ^a   Cunningham, Lea ^b   Zhang, Yue ^a   Rao, Yalan ^a   Nishimoto, Nahoko ^c   Nakagawa, Masahiro ^c   Olsson, Andre ^d   Wunderlich, Mark ^a   Link, Kevin A ^a   Mizukawa, Benjamin ^a   Grimes, H Leighton ^a,d   Kurokawa, Mineo ^c   Liu, P Paul ^b   Huang, Gang ^a   Mulloy, James C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LEUKEMOGENIC FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1-ETO FUSION PROTEIN, HUMAN; CBFB PROTEIN, HUMAN; CORE BINDING FACTOR BETA; MIXED LINEAGE LEUKEMIA PROTEIN; MLL-AF9 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BCL 2; RUNX1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIATION; GENETIC MODEL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; ANIMAL; APOPTOSIS; BONE MARROW CELL; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; METABOLISM; MISSENSE MUTATION; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MUTATION, MISSENSE; MYELOID CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84883534738     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68557     Document Type: Article

References (53)

1. Link KA, Chou FS, Mulloy JC. Core binding factor at the crossroads: determining the fate of the HSC. J Cell Physiol. 2010;222(1):50-56.
2. Kurokawa M. AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis. Int J Hematol. 2006;84(2):136-142. (Pubitemid 44343976)
3. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol. 2011;94(2):126-133.
4. Huang G, et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011;118(25):6544-6552.
5. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103(6):2316-2324. (Pubitemid 38326252)
6. Kohlmann A, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
7. Tang JL, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352-5361.
8. Schnittger S, et al. RUNX1 mutations are frequent in de novo AML with non complex karyotype and confer an unfavourable prognosis. Blood. 2011;117(8):2348-2357.
9. Motoda L, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007;25(12):2976-2986. (Pubitemid 350294422)
10. Jacob B, et al. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood. 2010;115(8):1610-1620.
11. Nishimoto N, et al. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood. 2011;118(9):2541- 2550.
12. Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
13. Kamikubo Y, et al. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell. 2010;17(5):455-468.
14. Hyde RK, et al. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. Blood. 2010;115(7):1433-1443.
15. Wunderlich M, Mulloy JC. Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction. Methods Mol Biol. 2009;538:263-285.
16. Mulloy JC, Wunderlich M, Zheng Y, Wei J. Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling. Cell Cycle. 2008;7(21):3314-3319.
17. Wunderlich M, Krejci O, Wei J, Mulloy JC. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood. 2006;108(5):1690-1697. (Pubitemid 44316139)
18. + hematopoietic cells using a single genetic element. Blood. 2003;102(13):4369-4376.
19. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99(1):15-23.
20. Wei J, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495. (Pubitemid 351763903)
21. Krejci O, et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 2008;111(4):2190-2199. (Pubitemid 351451533)
22. Mizukawa B, et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 2011;118(19):5235-5245.
23. Zuber J, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
24. Chou FS, et al. The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human pre-leukemia induced by AML1-ETO. Blood. 2012;120(4):709-719.
25. Ng KP, et al. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011;25(11):1739- 1750.
26. Imai Y, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96(9):3154-3160.
27. Munker R, et al. Characterization of a new myeloid leukemia cell line with normal cytogenetics (CGSH). Leuk Res. 2009;33(10):1405-1408.
28. Grimm D, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441(7092):537-541. (Pubitemid 44050158)
29. Yoshimi M, et al. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol. 2012;42(4):1044-1050.
30. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, Hogge DE. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia. 2003;17(4):760-763. (Pubitemid 36519373)
31. Cunningham L, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci U S A. 2012;109(36):14592-14597.
32. Wunderlich M, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24(10):1785-1788.
33. Goyama S, et al. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood. 2004;104(12):3558-3564. (Pubitemid 39564427)
34. Fukushima-Nakase Y, Naoe Y, Taniuchi I, Hosoi H, Sugimoto T, Okuda T. Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. Blood. 2005;105(11):4298-4307. (Pubitemid 40720776)
35. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20(4):723-733. (Pubitemid 32167637)
36. Dawson MA, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
37. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A. 1996;93(24):14059-14064. (Pubitemid 26424245)
38. Sykes SM, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146(5):697-708.
39. Ito K, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072-1078. (Pubitemid 351871736)
40. Klinakis A, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-233.
41. Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
42. Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
43. Hahn CN, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012-1017.
44. Ostergaard P, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43(10):929-931.
45. Neff T, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012;109(13):5028-5033.
46. Tanaka S, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120(5):1107- 1117.
47. Shi J, et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene. 2012;32(7):930-938.
48. Bernt KM, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
49. Wilkinson AC, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013;3(1):116-127.
50. Growney JD, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106(2):494-504. (Pubitemid 40981243)
51. Naoe Y, et al. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. J Exp Med. 2007;204(8):1749-1755. (Pubitemid 47236313)
52. Ichikawa M, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10(3):299-304. (Pubitemid 38667622)
53. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001;2(8):RESEARCH0032.